NCT03236987View on ClinicalTrials.gov

CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections

PHASE3RecruitingINTERVENTIONAL
Enrollment

424

Participants

Timeline

Start Date

February 5, 2018

Primary Completion Date

February 5, 2028

Study Completion Date

February 5, 2029

Conditions
Lung InfectionMycobacterium Avium Complex
Interventions
DRUG

Clarithromycin 1000 MG

The patient will be received for at least 12 months, a daily antibiotic treatment who is a combination of Clarithromycin, Ethambutol and Rifampicin.

DRUG

Azithromycin 250 mg

The patient will be received for at least 12 months, a daily antibiotic treatment who is a combination of Azithromycin, Ethambutol and Rifampicin.

DRUG

Rifampicin

The patient will be received for at least 12 months, a dailty antibiotic treatment who is a combination of Azithromycin or Clarithromycin (according to the randomisation), Ethambutol and Rifampicin.

DRUG

Ethambutol

The patient will be received for at least 12 months, a dailty antibiotic treatment who is a combination of Azithromycin or Clarithromycin (according to the randomisation), Ethambutol and Rifampicin.

Trial Locations (3)

13000

RECRUITING

Saint Joseph Hospital, Marseille

49933

RECRUITING

CHU Angers, Angers

80054

NOT_YET_RECRUITING

CHU Amiens Picardie, Amiens

All Listed Sponsors
lead

Centre Hospitalier Universitaire, Amiens

OTHER